BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26337079)

  • 1. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
    Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
    Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
    Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
    Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.
    Xie M; Vesuna F; Tantravedi S; Bol GM; Heerma van Voss MR; Nugent K; Malek R; Gabrielson K; van Diest PJ; Tran PT; Raman V
    Cancer Res; 2016 Nov; 76(21):6340-6350. PubMed ID: 27634756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.
    Inao T; Harashima N; Monma H; Okano S; Itakura M; Tanaka T; Tajima Y; Harada M
    Breast Cancer Res Treat; 2012 Jul; 134(1):89-100. PubMed ID: 22203435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.
    Botlagunta M; Kollapalli B; Kakarla L; Gajarla SP; Gade SP; Dadi CL; Penumadu A; Javeed S
    Bioinformation; 2016; 12(7):347-353. PubMed ID: 28246464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication.
    Yedavalli VS; Zhang N; Cai H; Zhang P; Starost MF; Hosmane RS; Jeang KT
    J Med Chem; 2008 Aug; 51(16):5043-51. PubMed ID: 18680273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
    Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
    Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.
    Wilky BA; Kim C; McCarty G; Montgomery EA; Kammers K; DeVine LR; Cole RN; Raman V; Loeb DM
    Oncogene; 2016 May; 35(20):2574-83. PubMed ID: 26364611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
    Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
    Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.
    Heerma van Voss MR; Vesuna F; Bol GM; Afzal J; Tantravedi S; Bergman Y; Kammers K; Lehar M; Malek R; Ballew M; Ter Hoeve N; Abou D; Thorek D; Berlinicke C; Yazdankhah M; Sinha D; Le A; Abrahams R; Tran PT; van Diest PJ; Raman V
    Oncogene; 2018 Jan; 37(1):63-74. PubMed ID: 28869602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
    Kukhanova MK; Karpenko IL; Ivanov AV
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
    Lin WL; Lee YJ; Wang SM; Huang PY; Tseng TH
    Eur J Pharmacol; 2012 Apr; 680(1-3):8-15. PubMed ID: 22329896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.
    Bol GM; Vesuna F; Xie M; Zeng J; Aziz K; Gandhi N; Levine A; Irving A; Korz D; Tantravedi S; Heerma van Voss MR; Gabrielson K; Bordt EA; Polster BM; Cope L; van der Groep P; Kondaskar A; Rudek MA; Hosmane RS; van der Wall E; van Diest PJ; Tran PT; Raman V
    EMBO Mol Med; 2015 May; 7(5):648-69. PubMed ID: 25820276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly.
    Cui BC; Sikirzhytski V; Aksenova M; Lucius MD; Levon GH; Mack ZT; Pollack C; Odhiambo D; Broude E; Lizarraga SB; Wyatt MD; Shtutman M
    Biochem Pharmacol; 2020 Dec; 182():114280. PubMed ID: 33049245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
    Samal SK; Routray S; Veeramachaneni GK; Dash R; Botlagunta M
    Sci Rep; 2015 Apr; 5():9982. PubMed ID: 25918862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines.
    Rampogu S; Kim SM; Son M; Baek A; Park C; Lee G; Kim Y; Kim GS; Kim JH; Lee KW
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32512851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway.
    Chen HH; Yu HI; Cho WC; Tarn WY
    Oncogene; 2015 May; 34(21):2790-800. PubMed ID: 25043297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:-an in silico and in vitro approach.
    Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
    Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer.
    Su CY; Lin TC; Lin YF; Chen MH; Lee CH; Wang HY; Lee YC; Liu YP; Chen CL; Hsiao M
    Oncotarget; 2015 Jul; 6(21):18602-12. PubMed ID: 26087195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.